Sign in
cache/89f766ad26ef08d3692a413bb90df99f1f1ea1bb4ef4b8e10c78cf32a1f758a4

EURONEXT:MDMA

Pharmala Biotech Holdings Inc.

  • Stock

Last Close

0.11

26/07 13:55

Volume Today

15.54K

Avg: 2.03M

PE Ratio

−61.79

PFCF: −36.83

OverviewFinancialsFilingspeopleAPIChartData
Income StatementBalance SheetCash FlowKey MetricsRatios
Quarterly
Yearly

Preview

Full access to financials is available to subscribers only. Please support our work and get full access to all features. You can cancel anytime. If you'd like a demo, free trial or have any questions, please checkout the help page

Subscribe NowHelp
Aug '21
Aug '22
Aug '23
net income
-2.51M
-
-985.58K
60.72%
-779.81K
20.88%
depreciation and amortization
303
-
12.13K
3,904.95%
52.77K
334.82%
deferred income tax
-368.12K
-
16.86K
104.58%
stock based compensation
142.62K
-
236.53K
65.85%
67.72K
71.37%
change in working capital
109.00K
-
111.55K
2.33%
376.86K
237.85%
accounts receivables
-29.48K
-
-23.22K
21.24%
-114.55K
393.40%
inventory
-116.34K
-
-5.85K
94.97%
accounts payables
214.04K
-
other working capital
138.48K
-
251.10K
81.33%
283.22K
12.79%
other non cash items
2.08M
-
368.12K
82.33%
-74.06K
120.12%
net cash provided by operating activities
-173.57K
-
-625.37K
260.29%
-339.66K
45.69%
investments in property plant and equipment
-262.19K
-
-994.87K
279.45%
-506.74K
49.07%
acquisitions net
891.40K
-
purchases of investments
sales maturities of investments
other investing activites
net cash used for investing activites
629.22K
-
-994.87K
258.11%
-506.74K
49.07%
debt repayment
common stock issued
83.44K
-
189.29K
-
common stock repurchased
dividends paid
other financing activites
1.93M
-
net cash used provided by financing activities
2.02M
-
189.29K
-
effect of forex changes on cash
net change in cash
2.47M
-
-1.62M
165.53%
-657.10K
59.44%
cash at beginning of period
2.47M
-
852.14K
65.53%
cash at end of period
2.47M
-
852.14K
65.53%
195.04K
77.11%
operating cash flow
-173.57K
-
-625.37K
260.29%
-339.66K
45.69%
capital expenditure
-262.19K
-
-994.87K
279.45%
-506.74K
49.07%
free cash flow
-435.76K
-
-1.62M
271.82%
-846.39K
47.76%

All numbers in (except ratios and percentages)